🧬Colossal Biosciences Valued at $10B After Generating Revenue
Colossal Biosciences Eyes $20-30B Valuation in New Round
TL;DR
Colossal Biosciences, the de-extinction startup, has started generating revenue and is eyeing a new funding round at a $20-30 billion valuation. The company's technology could have applications beyond conservation.
Colossal Biosciences, known for its ambitious goal of bringing back extinct species like the woolly mammoth, has begun to generate revenue over the last year and is now in talks to raise new funding at a $20-30 billion valuation. This startup isn't just about reviving ancient animals; it's also spinning out technologies with applications in human fertility treatment and conservation efforts. If you're tracking biotech startups or interested in genetic engineering, Colossal Biosciences' progress is worth watching as they continue to expand their scope beyond de-extinction into practical applications like artificial animal wombs and biodiversity credits.
Key Points
Colossal Biosciences has started to generate revenue over the last year, marking its first financial milestone since founding in 2018.
The company is in talks for a new funding round at a $20-30 billion valuation, aiming to raise significant capital from undisclosed investors.
Colossal Biosciences has spun out three startups: Breaking, Form Bio, and Astromech, with Astromech valued at $2 billion as of March 2023.
The company's core de-extinction business is expanding, adding the bluebuck antelope to its list of target species alongside woolly mammoths and dodo birds.
Colossal Biosciences plans to spin off artificial animal womb technology next year, which could have applications in human fertility treatment.
Why It Matters
If you're tracking biotech startups or interested in genetic engineering, Colossal Biosciences' progress is worth watching. Their work on de-extinction and conservation technologies has real-world implications for biodiversity credits and human fertility treatments.
Frequently Asked Questions
Why does this matter?
If you're tracking biotech startups or interested in genetic engineering, Colossal Biosciences' progress is worth watching. Their work on de-extinction and conservation technologies has real-world implications for biodiversity credits and human fertility treatments.
What happened?
Colossal Biosciences, the de-extinction startup, has started generating revenue and is eyeing a new funding round at a $20-30 billion valuation. The company's technology could have applications beyond conservation.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.